Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

"We look forward to future research efforts to further elucidate the role of AGEs in gastrointestinal complications including diabetic intestinal dysfunction, diabetic enteropathy and diabetic gastroparesis and the role that alagebrium may play in those disease."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties in
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Young Innovations ("Young"), a leading global ... the acquisition of the professional dental contract manufacturing ... MPL PDCMD manufactures fluoride varnish, prophy paste and ... procedures. "This acquisition marks the ... high-growth segments," said Dave Sproat , CEO ...
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... second quarter and six months ended June 30, 2015. ... in ITP are progressing and we continue to expect ... Rodriguez , president and chief executive officer of Rigel. ... other clinical programs, including evaluating fostamatinib for new treatment ...
(Date:8/4/2015)... SEATTLE , Aug. 4, 2015  Dr. ... Institute states the potential FDA approval of flibanserin, ... sets women and the treatment of decreased female ... women has many root causes and addressing libido ... is dangerous. ...
Breaking Medicine Technology:Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... June 30, 2011 UCB and Harvard University officially ... that took place in Boston last night in the ... (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) ... industry and academia, with Harvard scientists continuing their research ...
... -- Golden Meditech Holdings Limited ("Golden ... "Group," - 801.HK; 910801.TW), a leading integrated healthcare ... Group,s annual results for the year ended 31 ... core businesses reported total turnover of HK$328,066,000, 15% ...
Cached Medicine Technology:UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3Golden Meditech FY2010-11 Annual Results 2Golden Meditech FY2010-11 Annual Results 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... One of ... interviews to discuss his new book, The Pain Antidote , which provides strategies ... of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction ...
(Date:8/4/2015)... ... 04, 2015 , ... 24/7 Care At Home , a provider of ... today announced that the U.S. Department of Veteran’s Affairs (VA) has awarded its agency ... is well on the path to meeting the aspirational goals the VA promotes each ...
(Date:8/4/2015)... ... 04, 2015 , ... Increasingly, patients are researching online to ... In an effort to share more and better information with these savvy and ... share patient satisfaction ratings and comments about its doctors and advanced practice providers. ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, the healthcare industry ... its executive leadership team as Senior Vice President of Sales and Marketing. Mr. ... expanding global markets with a special emphasis on the healthcare industry. , Today, ...
(Date:8/4/2015)... NJ (PRWEB) , ... August 04, 2015 , ... Montclair ... Arts and Health, the first of its kind in New Jersey, which starting this ... of the Arts and Graduate School partnered with Atlantic Health System, one of the ...
Breaking Medicine News(10 mins):Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3
... all Sites from a Single ... ... chosen multiple products from Sage Software - including the,Intergy by Sage Practice ... the,patient experience. Previously, Digestive Specialists used The Medical,Manager by Sage., "We ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... key milestones in 2008 for its clinical,development programs, ... provided financial guidance for 2008., "During 2007, ...
... from Stanford University, ... Diego State University, CENTER VALLEY, Pa., March ... opto-digital solutions in healthcare,life science and consumer electronics ... Innovation Award Program: Tom Byers, Ph.D. and Tina,Seelig, ...
... CHICAGO, March 24 Linden LLC, a health care ... of a controlling,interest in its portfolio company, Ranir LLC, ... P. Kiphart. In addition to being a private,investor, Mr. ... Company.,Linden acquired Ranir in April 2005 and will maintain ...
... HealthMEDX, Inc. (HMX),the leading provider of Web-based ... has partnered with Silverchair Learning Systems to,offer ... Silverchair,s Learning Management System is a ... that delivers, tracks,and reports on educational programs ...
... finds they,re not getting needed screenings for breast and cervical ... review of 32 studies suggests that obese women -- particularly ... screenings for breast and cervical cancer. , No one ... avoid mammograms or Pap smears. And it,s not known why ...
Cached Medicine News:Health News:Multi-site Gastro Practice Chooses Intergy by Sage Practice Management System 2Health News:Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance 2Health News:Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance 3Health News:Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance 4Health News:Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance 5Health News:Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance 6Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 3Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 4Health News:Linden Announces Sale of Ranir to Kayak Holdings 2Health News:Linden Announces Sale of Ranir to Kayak Holdings 3Health News:HealthMEDX Partners With Silverchair Learning Systems 2Health News:Obese Women Less Likely to Be Tested for Some Cancers 2
... is a unique microprocessor controlled shaking incubator ... either 96 or 384 well format. Speed, ... control panel and all are displayed on ... the clear protective cover. The Millennium 2000 ...
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
... Ultracompact high end desktop multilaser flow ... any kind of cell analysis and absolute ... forward and two different side scatter signals ... channels. The new CyFlow ML instrument can ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: